MI-O-101

MI-O-101 is an experimental intra-tumoral immuno-oncology therapy derived from the plant cowpea mosaic virus (CPMV), a non-contagious pathogen in humans and animals, being developed to convert immunologically “cold” tumors into “hot” tumors that are susceptible to immune-mediated clearance.[1] Administered directly into tumors, the CPMV nanoparticles are recognized as foreign by pattern recognition receptors such as Toll-like receptors on innate immune cells within the tumor microenvironment, triggering robust innate immune activation, tumor cell killing, and subsequent exposure and processing of tumor-associated antigens to drive systemic adaptive, tumor-specific immunity.[1] Preclinical data across multiple cancer models, including melanoma, breast, ovarian, brain, and lung tumors, have shown potent single-agent anti-tumor activity as well as enhanced efficacy when combined with radiation, chemotherapy, immune checkpoint inhibitors, and vaccines, and the platform has demonstrated anti-tumor effects in naturally occurring canine cancers, supporting both human and veterinary applications.[1] MI-O-101 is being advanced by Mosaic ImmunoEngineering, which is pursuing regulatory pathways toward first-in-human trials and exploring its broader use as a modular immunotherapy and vaccine adjuvant platform in oncology and infectious disease.[1]

Other names

cowpea mosaic virus immunotherapyCPMV-based intra-tumoral immunotherapy